Valuation: Nektar Therapeutics

Market Cap 2.34B 2.06B 1.91B 1.76B 3.3B 227B 3.36B 22.9B 8.93B 111B 8.8B 8.61B 384B P/E 2026 *
-7.7x
P/E 2027 * -6.39x
Enterprise Value 2.34B 2.06B 1.91B 1.76B 3.3B 227B 3.36B 22.9B 8.93B 111B 8.8B 8.61B 384B EV / Sales 2026 *
56.5x
EV / Sales 2027 * 63.4x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.06%
1 week+3.45%
Current month-0.64%
1 month+4.00%
3 months-24.00%
6 months+86.90%
Current year+64.05%
1 week 64.24
Extreme 64.24
70.99
1 month 61.29
Extreme 61.29
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.02
Extreme 21.02
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
6/30/26 A Sell

Chief Technology Officer

-5,681 0.0168%
6/17/26 A Sell

Chief Executive Officer

-10,000 0.0296%
6/15/26 A Sell

Chief Technology Officer

-5,538 0.0164%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%+3.45%+177.44%+730.31% 2.34B
+1.23%+0.35%+51.62%+87.98% 55.92B
+2.84%+8.99%+65.91%+71.14% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-0.83%+0.78%+25.36%-30.09% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average -0.02%+1.48%+55.47%+226.63% 24.43B
Weighted average by Cap. +0.64%+3.18%+44.99%+141.92%

Financials

2026 *2027 *
Net sales 41.44M 36.45M 33.86M 31.14M 58.41M 4.01B 59.45M 405M 158M 1.96B 156M 152M 6.79B 36.99M 32.53M 30.22M 27.79M 52.12M 3.58B 53.06M 361M 141M 1.75B 139M 136M 6.06B
Net income -249M -219M -204M -187M -351M -24.13B -357M -2.43B -950M -11.77B -935M -915M -40.83B -351M -309M -287M -264M -494M -33.97B -503M -3.43B -1.34B -16.57B -1.32B -1.29B -57.48B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
23/07/26 $69.36 +0.06% 631,124
22/07/26 $69.32 +0.95% 508,631
21/07/26 $68.67 +5.91% 1,294,048
20/07/26 $64.84 -5.01% 748,033
17/07/26 $68.26 +1.80% 538,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
69.36USD
Average target price
153.22USD
Spread / Average Target
+120.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock